A method has been developed for the selective delivery of lipophilic immunomodulators to macrophages, which results in the induction of antitumor activity. This method utilizes exhaustively acetylated low density lipoprotein (acetyl-LDL) effector-to-target ratio using 18 ,sg of the acetyl-LDL:MTPPtdEtn complex containing 3.6 ,ig of MTP-PtdEtn (=80 molecules per particle). These studies describe a method for the induction of antitumor activity by use of a chemically modified serum component, acetyl-LDL, to direct lipophilic immunomodulators to Mo.
effector-to-target ratio using 18 ,sg of the acetyl-LDL:MTPPtdEtn complex containing 3.6 ,ig of MTP-PtdEtn (=80 molecules per particle). These studies describe a method for the induction of antitumor activity by use of a chemically modified serum component, acetyl-LDL, to direct lipophilic immunomodulators to Mo.
The development of biological response modifiers to modulate antitumor activity has been an area of great interest (1) (2) (3) (4) (5) (6) . Muramyl dipeptide (MDP; N-acetylmuramyl-L-alanyl-Disoglutamine), a component of the mycobacterium cell wall, is a powerful inducer of antitumor activity in the macrophage (M*). MDP, however, is quickly excreted from the body and has limited usefulness for regimens in vivo (7) . The lipophilic derivative muramyl tripeptide phosphatidylethanolamine (MTP-PtdEtn; amide composed of N-acetylmuramyl-L-alanyl-D-isoglutamyl-L-alanine and dipalmitoyl phosphatidylethonolamine) (8) and MDP-dipalmitoylglycerol (9) have both been shown to activate MO for tumor cell destruction when encapsulated in liposomes. In addition, liposomes containing MTP-PtdEtn have been demonstrated to protect mice from fatal herpes simplex virus 2 infection in vitro and in vivo (10) . However, the nonspecificity of liposome-cell interactions and the inability of most liposome preparations to pass through the vascular endothelium is a disadvantage when used for targeting drugs or immune modulators to various tissues and parenchymal cells (11) .
Our interest in acetylated low density lipoproteins (LDL) as carriers of lipophilic biological response modifiers such as MTP-PtdEtn stems from their being prepared from small, naturally occurring plasma LDL particles (-25 nm in diameter) with an extensive hydrophobic domain. The uptake of exhaustively acetylated LDL (acetyl-LDL) by resident peritoneal MO and blood monocytes has been well characterized (12) . Most lipoproteins can pass from the vascular system into the body tissues (13) . Furthermore, it is now possible to sequester a variety of lipophilic drugs into lipoproteins (14) (15) (16) (17) (18) (19) '25I-labeled-acetyl-LDL ('25I-acetyl-LDL) was fractionated on a Sephadex G-15-120 column, dialyzed against buffer A, and filtered before use. Acetyl-LDL:MTP-PtdEtn Complex Formation. In a glass tube, MTP-PtdEtn (327 ,ug) was evaporated to dryness with argon, and 2-4 mg of acetyl-LDL was added in 2-3 ml of buffer A. The mixture was stirred gently with a Teflon-coated stirring bar for 2 hr in the dark at 37°C under argon. After incubation, the sample was loaded on a 1-cm x 10-cm column of Sephadex G-15-120, and the acetyl-LDL:MTPPtdEtn complex was collected. The complex was passed through a 0.45-,um Millex filter for removal of possible aggregated acetyl-LDL:MTP-PtdEtn and for sterilization. The average recovery of acetyl-LDL protein for the entire procedure was 85-90%.
The MTP-PtdEtn concentration was determined after Bligh and Dyer extraction (25) of the complex. The chloroform layer from the extraction procedure was evaporated and hydrolyzed in 6 N HCl/0.1% phenol for 12 hr. The hydrolyzed material was quantitated by using an amino acid analyzer, and the isoglutamate-to-alanine-to-ethanolamine ratio first is a one-step technique for determining the total binding and uptake of acetyl-LDL, which is not complicated by degradation steps that occur with iodinated apoproteins. Second, and more important for the present work with MTP-PtdEtn, DiI and MTP-PtdEtn both have two long acyl chains and represent lipophilic molecules being carried by acetyl-LDL. Consequently, monitoring the binding and uptake of Dii bound to acetyl-LDL is an excellent indicator for the uptake of lipophilic drug species such as MTP-PtdEtn.
We have prepared acetyl-LDL:MTP-PtdEtn-DiI complexes by the "'dry-fillm"' stirring technique described in Materials and Methods. Interaction of acetyl-LDL:MTP-PtdEtn-DiI with M4Y was determined by extracting the DiI and quantitating it by using a spectrofluorometer (Fig. 2) .
The uptake of acetyl-LDL:MTP-PtdEtn-DiI complex by
MQt at 370C showed saturation kinetics with maximal uptake at a concentration of~160 ,u&g of protein per ml. Competitive studies revealed the uptake of acetyl-LDL:MTP-PtdEtn-DiI by Myt to be highly specific. Unlabeled LDL and synthetic bilayers (liposomes) showed negligible-to-moderate competition with Dil-labeled acetyl-LDL:MTP-PtdEtn complex (Fig. 2 Inset) . Unlabeled acetyl-LDL was an effective competitive inhibitor of acetyl-LDL:MTP-PtdEtn-DiI (Fig. 2 Inset), illustrating that the complex was interacting with the MXt by means of the acetyl-LDL receptor.
These same experiments, when repeated using Dil-labeled liposome-MTP-PtdEtn complex, showed major differences between the specificity of liposomes and acetyl-LDL for peritoneal M+. When the cells were incubated with increasing amounts of liposome-MTP-PtdEtn-DiI, saturation was not achieved, and binding increased steadily in a linear fashion (Fig. 3) . In separate experiments, the uptake of liposome-MTP-PtdEtn-DiI continued to increase well beyond 3 hr. The uptake of liposome-MTP-PtdEtn--DiI showed little specificity, and competitive binding was observed for the three classes of lipid-containing particles, liposomes, acetyl-LDL, and LDL (Fig. 3 Inset).
Functional Activation of Peritoneal M+~. Next we determined if the complex was capable of inducing M4 antitumor cytostasis and cytotoxicity activity in Myt populations (29) . Table 1 shows that preincubation for 24 hr with acetyl-LDL: control, acetyl-LDL-treated Mo. The inclusion of excess liposomes with acetyl-LDL:MTP-PtdEtn showed no change in the cytostatic activity toward the tumor cell targets (Table  1) . MTP-PtdEtn encapsulated in liposomes composed of phosphatidylcholine and cholesterol augmented the cytostatic activity of thioglycolate-elicited Mo by 2-fold (Table 2 ).
This effect was not dose dependent as increasing the liposome-MTP-PtdEtn complex by 10-fold did not enhance the level of cytostasis. Thioglycolate-elicited Mo treated in vitro with the acetyl-LDL:MTP-PtdEtn complex demonstrated marked tumoricidal activity against P815 mastocytoma cells (Table 3) . At an effector-to-target cell ratio of 40:1, the acetyl-LDL:MTP-PtdEtn-treated Mo showed a 2.6 and 6.6 times increase in cytotoxicity during a 24-hr assay when compared to MTP-PtdEtn-or acetyl-LDL-treated M+, respectively. Mo effector-to-target ratios of 1:1 and 5:1 showed no significant differences between acetyl-LDL:MTP-PtdEtn-, MTP-PtdEtn-, and acetyl-LDL-treated groups when compared to the control group.
DISCUSSION
The current study indicates that acetyl-LDL:MTP-PtdEtn specifically interacts with and delivers an active lipophilic (effector-to-target ratio, 10:1). (30) (31) (32) . The pathway is functional in Mo, blood monocytes, sinusoidal endothelial cells, and to a lesser extent in microvascular endothelial cells (12, 28, 30, 31, 33, 34) . The in vivo function of the acetyl-LDL pathway has been suggested as a scavenger role for LDLs that are modified by oxidation products of arachidonic acid (12, 30) and/or as a role in Mo-induced inflammation (12) .
Cytostasis and cytotoxicity assays performed with the B16F10 melanoma and P815 mastocytoma tumor cells dem- Responsive peritoneal Mo are thought to require a primary signal (e.g., interferon y) to reach the "primed" state followed by a second "triggering" signal such as endotoxin or bacterial lipopolysaccharide to become fully "activated" (29, 35) . In our studies, cytostasis and cytotoxicity states were achieved by using acetyl-LDL:MTP-PtdEtn complex without the need for a second signal. 
